Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Securities Fraud Worries Reduced By Supreme Court Case

This article was originally published in The Pink Sheet Daily

Executive Summary

High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.

You may also be interested in...

Securities Fraud Class Action Suits Could Grow After Amgen’s Supreme Court Loss

Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.

Adverse Events Disclosures May Increase After Supreme Court Ruling Against Matrixx, But "Total Mix" Matters

Companies may have to disclose adverse event reports that are not statistically significant, but the court says the amount of disclosure needed can be limited by how much a company tells the market about an issue in general.

Supreme Court Lets Vioxx Securities Suit Against Merck Stand

The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts